Toroslu Tolgahan, Erdoğan Halil, Çağlar Özge, Güçlü Oğuz, Dereköy Fevzi Sefa
Department of Otorhinolaryngology, Çanakkale Onsekiz Mart University School of Medicine, Çanakkale, Turkey.
Department of Otorhinolaryngology, Elazığ Kovancılar State Hospital, Elazığ, Turkey.
Turk Arch Otorhinolaryngol. 2018 Dec;56(4):226-232. doi: 10.5152/tao.2017.2337. Epub 2018 Dec 21.
To evaluate the effectiveness of different therapies for idiopathic sudden sensorineural hearing loss and prognostic factors, and determine the most successful treatment according to the audiogram type and time from onset to treatment.
A total of 90 cases from February 2009 to January 2015 were classified under Group I oral treatment (methylprednisolone, acyclovir, betahistine-dihydrochloride, and vitamin B12); Group II oral treatment + intratympanic steroids (ITS); Group III oral treatment + hyperbaric oxygen; and Group IV only ITS. A pure tone average (PTA) improvement of less than 10 dB was assessed as "no improvement," a PTA of 10 dB or more or a 10% or more increase in the speech discrimination score (SDS) as "partial improvement," and a hearing threshold within 10 dB and SDS within 5%-10% of the unaffected ear as "full improvement."
Overall, 32.2% patients showed full and 28.9% showed partial improvement, whereas 38.9% showed no improvement. There was no significant difference in terms of mean hearing gain between the different treatment methods. As the degree of hearing loss and time from onset to treatment increased, improvement worsened (p<0.05). Descending audiogram had lower mean hearing gains compared to other groups (p=0.014). There was no significant effect of age, sex, tinnitus and/or vertigo, and systemic disease on treatment success (p>0.05).
The most important factors affecting prognosis were the time from onset to treatment, hearing loss severity, and audiogram type. Only ITS avoided side effects and reduced hospitalization. ITS in the first two weeks, followed by hyperbaric oxygen were considered as the treatment priority.
评估特发性突发性感音神经性听力损失不同治疗方法的有效性及预后因素,并根据听力图类型和从发病到治疗的时间确定最成功的治疗方法。
2009年2月至2015年1月共90例患者被分为四组:第一组为口服治疗(甲泼尼龙、阿昔洛韦、倍他司汀二盐酸盐和维生素B12);第二组为口服治疗+鼓室内注射类固醇(ITS);第三组为口服治疗+高压氧;第四组仅采用ITS。纯音平均听阈(PTA)改善小于10 dB被评估为“无改善”,PTA改善10 dB或更多或言语识别率(SDS)提高10%或更多被评估为“部分改善”,听力阈值在未受影响耳的10 dB以内且SDS在5%-10%以内被评估为“完全改善”。
总体而言,32.2%的患者完全改善,28.9%的患者部分改善,而38.9%的患者无改善。不同治疗方法之间的平均听力增益无显著差异。随着听力损失程度和从发病到治疗的时间增加,改善情况变差(p<0.05)。与其他组相比,下降型听力图的平均听力增益较低(p=0.014)。年龄、性别、耳鸣和/或眩晕以及全身性疾病对治疗成功率无显著影响(p>0.05)。
影响预后的最重要因素是从发病到治疗的时间、听力损失严重程度和听力图类型。仅ITS可避免副作用并减少住院时间。优先考虑在前两周进行ITS,随后进行高压氧治疗。